@Boffin99
It's a very average evaluation of value and potential.
32% chance of success for a drug that leads single-agent efficacy and is comparable to combinations in R/R AML with a differentiated first-in-class mechanism of action in FTO inhibition.
For those with the motivation to look, there is an enormous amount of data out there supporting FTO inhibition and CPACS. For a potent example, of 4 patients who were refractory to two courses of combination antimetabolites, 3 achieved durable complete responses (75%) after a single 7-day dose of Bisantrene.
40-years later the mechanism of Ara-C resistance, and sensitivity to Bisantrene may be understood.
@hotcongo probably the company that owns the IP to the reformulation of Bisantrene with a 20-year patent life. Seriously.
@Boffin99It's a very average evaluation of value and potential....
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.83 |
Change
-0.030(1.61%) |
Mkt cap ! $311.7M | |||
| Open | High | Low | Value | Volume |
| $1.86 | $1.91 | $1.79 | $169.3K | 92.02K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 92 | $1.83 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.87 | 3472 | 1 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |